Company intelligence / Profile preview

Chengdu Saijie Pharmaceutical Technology

Chengdu, Sichuan, China

Ownership: Private
Development stage: Other

Overview

Chengdu Saijie Pharmaceutical Technology is a Chinese biotechnology company focused on the research and development of innovative small molecule drugs for metabolic and endocrine diseases. The company specializes in the discovery of multi-target agonists, particularly those targeting the GLP-1, GCG, and GIP receptors to treat conditions such as type 2 diabetes and obesity. Saijie Pharmaceutical leverages its medicinal chemistry expertise to develop oral alternatives to existing injectable peptide therapies. The firm is part of the growing cluster of life science innovators located in the Chengdu High-tech Zone.

Therapeutic areas: EndocrinologyGastroenterology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Chengdu Saijie Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chengdu Saijie Pharmaceutical Technology.

Explore the full profile